Part 2: mucormycosis: focus on therapy

References

• Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17:1859–1867.
   PubMed Web of Science ®Google Scholar
• Sun HY, Forrest G, Gupta KL, et al. Rhino-orbital-cerebral zygomycosis in solid organ transplant recipients. Transplantation. 2010;90:85–92.
   PubMed Web of Science ®Google Scholar
• Ruping MJ, Heinz WJ, Kindo AJ, et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother. 2010;65(2):296–302. doi:10.1093/jac/dkp430
   PubMed Web of Science ®Google Scholar
• Ma J, Jia R, Li J, et al. Retrospective clinical study of eighty-one cases of intracranial mMucormycosis. J Glob Infect Dis. 2015;7:143–150. DOI:10.4103/0974-777X.170497
   PubMedGoogle Scholar
• Patel A, Kaur H, Xess I, et al. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect. 2020;26:944 e9–e15 . DOI:10.1016/j.cmi.2019.11.021
   PubMed Web of Science ®Google Scholar
• Kyvernitakis A, Torres HA, Jiang Y, et al. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. Clin Microbiol Infect. 2016;22:811 e1–e8.
   PubMed Web of Science ®Google Scholar
• Sanghvi D, Kale H. Imaging of COVID-19-associated craniofacial mucormycosis: a black and white review of the “black fungus”. Clin Radiol. 2021;76(11):812–819. DOI:10.1016/j.crad.2021.07.004.
   PubMed Web of Science ®Google Scholar
• Skiada A, Lanternier F, Groll AH, et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica. 2013;98:492–504. doi:10.3324/haematol.2012.065110
   PubMed Web of Science ®Google Scholar
• Giudice G, Cutrignelli DA, Sportelli P, et al. Rhinocerebral mucormycosis with orosinusal involvement: diagnostic and surgical treatment guidelines. Endocr Metab Immune Disord Drug Targets. 2016;16:264–269. doi:10.2174/1871530316666161223145055
   PubMed Web of Science ®Google Scholar
• Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102(3):433–444. doi:10.3324/haematol.2016.152900
   PubMed Web of Science ®Google Scholar
• Jenks JD, Salzer HJ, Prattes J, et al. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy. Drug Des Devel Ther. 2018;12:1033–1044. doi:10.2147/DDDT.S145545
   PubMed Web of Science ®Google Scholar
• Badali H, Canete-Gibas C, McCarthy D, et al. Epidemiology and antifungal susceptibilities of mucoralean fungi in clinical samples from the United States. J Clin Microbiol. 2021;59(9):e0123021. doi:10.1128/JCM.01230-21
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Azie N, Franks B, et al. Prospective antifungal therapy (PATH) alliance((R)): focus on mucormycosis. Mycoses. 2014;57:240–246. doi: 10.1111/myc.12149
   PubMed Web of Science ®Google Scholar
• Imhof A, Balajee SA, Fredricks DN, et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis. 2004;39(5):743–746. doi:10.1086/423274
   PubMed Web of Science ®Google Scholar
• Rudramurthy SM, Hoenigl M, Meis JF, et al. ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. Mycoses. 2021;64(9):1028–1037. doi:10.1111/myc.13335
   PubMed Web of Science ®Google Scholar
• Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47:503–509.
   PubMed Web of Science ®Google Scholar
• Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634–653.
   PubMed Web of Science ®Google Scholar
• Lanternier F, Poiree S, Elie C, et al. Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. J Antimicrob Chemother. 2015;70(11):3116–3123. doi:10.1093/jac/dkv236
   PubMed Web of Science ®Google Scholar
• Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19:e405–e21. doi:10.1016/S1473-3099(19)30312-3
   PubMed Web of Science ®Google Scholar
• Shoham S, Magill SS, Merz WG, et al. Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases. Med Mycol. 2010;48(3):511–517. doi:10.3109/13693780903311944
   PubMed Web of Science ®Google Scholar
• Tedder M, Spratt JA, Anstadt MP, et al. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg. 1994;57:1044–1050.
   PubMed Web of Science ®Google Scholar
• Song Y, Qiao J, Giovanni G, et al. Mucormycosis in renal transplant recipients: review of 174 reported cases. BMC Infect Dis. 2017;17(1):283. doi:10.1186/s12879-017-2381-1
   PubMed Web of Science ®Google Scholar
• Legouge C, Caillot D, Chretien ML, et al. The reversed halo sign: pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia? Clin Infect Dis. 2014;58(5):672–678. doi:10.1093/cid/cit929
   PubMed Web of Science ®Google Scholar
• Almyroudis NG, Sutton DA, Linden P, et al. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant. 2006;6(10):2365–2374. doi:10.1111/j.1600-6143.2006.01496.x
   PubMed Web of Science ®Google Scholar
• Chakrabarti A, Das A, Mandal J, et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol. 2006;44(4):335–342. doi:10.1080/13693780500464930
   PubMed Web of Science ®Google Scholar
• Kaur H, Ghosh A, Rudramurthy SM, et al. Gastrointestinal mucormycosis in apparently immunocompetent hosts-A review. Mycoses. 2018;61:898–908. doi: 10.1111/myc.12798
   PubMed Web of Science ®Google Scholar
• Ziaka M, Papakonstantinou E, Vasileiou E, et al. Paediatric cutaneous mucormycosis: a case report and review of the literature. Mycoses. 2022;65(7):674–682. doi:10.1111/myc.13452
   PubMed Web of Science ®Google Scholar
• Datarkar A, Bhawalkar A, Daware S, et al. Anti-fungal therapy: an overview for maxillofacial surgeons in post-covid-19 fungal infections. Natl J Maxillofac Surg. 2022;13(3):330–336. doi:10.4103/njms.njms_412_21
   PubMedGoogle Scholar
• Gupta S, Goil P, Mohammad A, et al. Mucormycosis management in COVID-19 era: is immediate surgical debridement and reconstruction the answer? Arch Plast Surg. 2022;49(3):397–404. doi:10.1055/s-0042-1748654
   PubMedGoogle Scholar
• Sen M, Honavar SG, Bansal R, et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. Indian J Ophthalmol. 2021;69:1670–1692.
   PubMed Web of Science ®Google Scholar
• Moorthy A, Nayak T, Bachalli PS, et al. COVID-associated rhinocerebral mucormycosis: a retrospective analysis of presentation and outcomes. Eur Arch Otorhinolaryngol. 2022;208:1–9.
   Google Scholar
• Thajeb P, Thajeb T, Dai D. Fatal strokes in patients with rhino-orbito-cerebral mucormycosis and associated vasculopathy. Scand J Infect Dis. 2004;36(9):643–648. doi:10.1080/00365540410020794.
   PubMed Web of Science ®Google Scholar
• Okwechime RT, Reyes N, Trivedi D, et al. Bilateral cerebral mucormycosis in an immunocompetent female. Ochsner J. 2022;22(2):169–175. doi:10.31486/toj.21.0088
   PubMed Web of Science ®Google Scholar
• Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014;20(Suppl 3):5–26. doi:10.1111/1469-0691.12371
   PubMed Web of Science ®Google Scholar
• Biddeci G, Antonello M, Pizzi M, et al. Mucormycosis with peculiar aortic involvement in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2020;37(2):164–169. doi:10.1080/08880018.2019.1691294
   PubMed Web of Science ®Google Scholar
• Coffey MJ, Fantone J, Stirling MC, et al. Pseudoaneurysm of pulmonary artery in mucormycosis. Radiographic characteristics and management. Am Rev Respir Dis. 1992;145:1487–1490. doi:10.1164/ajrccm/145.6.1487
   PubMedGoogle Scholar
• Athanasiadou KI, Athanasiadis DI, Constantinidis J, et al. Successful treatment of rhinoorbital mucormycosis due to Rhizopus arrhizus with liposomal amphotericin B, posaconazole and surgical debridement in a child with neuroblastoma. Med Mycol Case Rep. 2019;25:10–14. doi:10.1016/j.mmcr.2019.06.003
   PubMed Web of Science ®Google Scholar
• Gamaletsou MN, Sipsas NV, Roilides E, et al. Rhino-orbital-cerebral mucormycosis. Curr Infect Dis Rep. 2012;14(4):423–434. doi:10.1007/s11908-012-0272-6
   PubMed Web of Science ®Google Scholar
• Ziakas PD, Adraktas P, Ntountas J, et al. Isolated orbital mucormycosis: a rare presentation ending in a fatal outcome. Int J Infect Dis. 2009;13(1):112–114. doi:10.1016/j.ijid.2008.01.015
   PubMed Web of Science ®Google Scholar
• Eldsouky SM, Shahat AK, Al-Tabbakh AM, et al. Clinical and mycological investigations of post-COVID-19 acute invasive fungal sinusitis. Laryngoscope Investig Otolaryngol. 2022;7:1780–1789. doi:10.1002/lio2.956
   PubMed Web of Science ®Google Scholar
• Saluja G, Bhari A, Pushker N, et al. Experience on rhino-orbital mucormycosis from a tertiary care hospital in the first wave of COVID-19: an Indian perspective. Med J Armed Forces India. 2022. doi:10.1016/j.mjafi.2022.01.009
   PubMedGoogle Scholar
• Hoenigl M, Seidel D, Carvalho A, et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe. 2022;3(7):e543–e552. doi:10.1016/S2666-5247(21)00237-8
   PubMedGoogle Scholar
• Muthu V, Agarwal R, Rudramurthy SM, et al. Multicenter case-control study of COVID-19-Associated Mucormycosis Outbreak, India. Emerg Infect Dis. 2023;29:8–19. doi:10.3201/eid2901.220926
   PubMed Web of Science ®Google Scholar
• Patel M, Panchal J, Desai C, et al. Emergence of cerebral mucormycosis in the Post-COVID Period: a detailed analysis of risk factors, clinical progression, and management of this opportunistic fungal infection. Cureus. 2022;14:e31220. .
   PubMed Web of Science ®Google Scholar
• Rizvi SWA, Khan S, Shahbaz M, et al. Long-term outcomes of transcutaneous retrobulbar amphotericin B in COVID-19-associated mucormycosis. Indian J Ophthalmol. 2023;71(2):452–456. doi:10.4103/ijo.IJO_1382_22
   PubMed Web of Science ®Google Scholar
• Kamath S, Kumar M, Sarkar N, et al. A study of profile of mucormycosis during the second wave of COVID-19 in a tertiary care hospital. Cureus. 2022;14:e21054. doi:10.7759/cureus.21054
   PubMedGoogle Scholar
• Gupta U, Paliwal D, Rawat S. Mucormycosis in India: pathophysiology and perspectives on treatment and management. Infect Disord Drug Targets. 2022, May 9;22.
   Google Scholar
• Chaurpagar R, Chiplunkar B, Doifode P, et al. Study of clinicoepidemiology and surgical complications in acute invasive fungal rhinosinusitis. Indian J Otolaryngol Head Neck Surg. 2023;75:1–8. doi: 10.1007/s12070-022-03430-5
   Web of Science ®Google Scholar
• Sirohiya P, Vig S, Mathur T, et al. Airway management, procedural data, and in-hospital mortality records of patients undergoing surgery for mucormycosis associated with coronavirus disease (COVID-19). J Mycol Med. 2022;32(4):101307. doi:10.1016/j.mycmed.2022.101307
   PubMed Web of Science ®Google Scholar
• Chretien ML, Legouge C, Pages PB, et al. Emergency and elective pulmonary surgical resection in haematological patients with invasive fungal infections: a report of 50 cases in a single centre. Clin Microbiol Infect. 2016;22(9):782–787. doi:10.1016/j.cmi.2015.12.029
   PubMed Web of Science ®Google Scholar
• Feng J, Sun X. Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome. Infection. 2018;46(4):503–512. doi:10.1007/s15010-018-1149-x.
   PubMed Web of Science ®Google Scholar
• Pagano L, Ricci P, Tonso A, et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA infection program (Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto). Br J Haematol. 1997;99(2):331–336. doi:10.1046/j.1365-2141.1997.3983214.x
   PubMed Web of Science ®Google Scholar
• Hamilos G, Samonis G, Kontoyiannis DP. Pulmonary mucormycosis. Semin Respir Crit Care Med. 2011;32(6):693–702. doi:10.1055/s-0031-1295717.
   PubMed Web of Science ®Google Scholar
• Sun HY, Aguado JM, Bonatti H, et al. Pulmonary zygomycosis in solid organ transplant recipients in the current era. Am J Transplant. 2009;9:2166–2171.
   PubMedGoogle Scholar
• Lee JH, Hyun JS, Kang DY, et al. Rare complication of bronchoesophageal fistula due to pulmonary mucormycosis after induction chemotherapy for acute myeloid leukemia: a case report. J Med Case Rep. 2016;10(1):195–197. DOI:10.1186/s13256-016-0991-7
   PubMedGoogle Scholar
• Chamilos G, Marom EM, Lewis RE, et al. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis. 2005;41(1):60–66. DOI:10.1086/430710
   PubMed Web of Science ®Google Scholar
• Mills SEA, Yeldandi AV, Odell DD. Surgical treatment of multifocal pulmonary mucormycosis. Ann Thorac Surg. 2018;106:e93–e5. doi: 10.1016/j.athoracsur.2017.12.033
   PubMed Web of Science ®Google Scholar
• Vercillo MS, Liptay MJ, Seder CW. Early pneumonectomy for pulmonary mucormycosis. Ann Thorac Surg. 2015;99(3):e67–8. doi:10.1016/j.athoracsur.2014.11.061.
   PubMed Web of Science ®Google Scholar
• Lee E, Vershvovsky Y, Miller F, et al. Combined medical surgical therapy for pulmonary mucormycosis in a diabetic renal allograft recipient. Am J Kidney Dis. 2001;38(6):E37. DOI:10.1053/ajkd.2001.29293
   PubMed Web of Science ®Google Scholar
• Multani A, Reveron-Thornton R, Garvert DW, et al. Cut it out! Thoracic surgeon’s approach to pulmonary mucormycosis and the role of surgical resection in survival. Mycoses. 2019;62(10):893–907. DOI:10.1111/myc.12954
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Wessel VC, Bodey GP, et al. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 2000;30(6):851–856. DOI:10.1086/313803
   PubMed Web of Science ®Google Scholar
• Bao J, Liu C, Dong Y, et al. Clinical manifestations of pulmonary mucormycosis in recipients of allogeneic hematopoietic stem cell transplantation: a 21-Case series report and literature review. Can Respir J. 2022;2022:1237125. doi:10.1155/2022/1237125
   PubMed Web of Science ®Google Scholar
• Choi H, Lee H, Jeon K, et al. Factors affecting surgical resection and treatment outcomes in patients with pulmonary mucormycosis. J Thorac Dis. 2019;11:892–900.
   PubMed Web of Science ®Google Scholar
• McAdams HP, Rosado de Christenson M, Strollo DC, et al. Pulmonary mucormycosis: radiologic findings in 32 cases. AJR Am J Roentgenol. 1997;168(6):1541–1548. DOI:10.2214/ajr.168.6.9168721
   PubMed Web of Science ®Google Scholar
• Lee FY, Mossad SB, Adal KA. Pulmonary mucormycosis: the last 30 years. Arch Intern Med. 1999;159:1301–1309. doi: 10.1001/archinte.159.12.1301
   PubMed Web of Science ®Google Scholar
• Pulle MV, Puri HV, Asaf BB, et al. Outcomes of early anti-fungal therapy with aggressive surgical resection in pulmonary mucormycosis. Lung India. 2021;38(4):314–320. DOI:10.4103/lungindia.lungindia_758_20
   PubMed Web of Science ®Google Scholar
• Hicks WL Jr., Nowels K, Troxel J. Primary cutaneous mucormycosis. Am J Otolaryngol. 1995;16:265–268. doi: 10.1016/0196-0709(95)90155-8
   PubMed Web of Science ®Google Scholar
• Planegger A, Uyulmaz S, Poskevicius A, et al. Cutaneous invasive fungal infections with Saksenaea species in immunocompetent patients in Europe: a systematic review and case report. Plast Reconstr Surg Glob Open. 2022;10(4):e4230. DOI:10.1097/GOX.0000000000004230
   PubMedGoogle Scholar
• Li H, Hwang SK, Zhou C, et al. Gangrenous cutaneous mucormycosis caused by Rhizopus oryzae: a case report and review of primary cutaneous mucormycosis in China over past 20 years. Mycopathologia. 2013;176(1–2):123–128. DOI:10.1007/s11046-013-9654-z
   PubMed Web of Science ®Google Scholar
• Castrejon-Perez AD, Welsh EC, Miranda I, et al. Cutaneous mucormycosis. An Bras Dermatol. 2017;92(3):304–311. DOI:10.1590/abd1806-4841.20176614
   PubMed Web of Science ®Google Scholar
• Lelievre L, Garcia-Hermoso D, Abdoul H, et al. Posttraumatic mucormycosis: a nationwide study in France and review of the literature. Medicine (Baltimore). 2014;93(24):395–404. DOI:10.1097/MD.0000000000000221
   PubMed Web of Science ®Google Scholar
• Skiada A, Drogari-Apiranthitou M, Pavleas I, et al. Global cutaneous mucormycosis: a systematic review. J Fungi (Basel). 2022;8(2):8.194–9. doi:10.3390/jof8020194
   PubMedGoogle Scholar
• Dannaoui E. Antifungal resistance in mucorales. Int J Antimicrob Agents. 2017;50(5):617–621. doi:10.1016/j.ijantimicag.2017.08.010.
   PubMed Web of Science ®Google Scholar
• Clark NM, Grim SA, Lynch JP 3rd. Posaconazole: use in the prophylaxis and treatment of fungal infections. Semin Respir Crit Care Med. 2015;36:767–785. doi: 10.1055/s-0035-1562902
   PubMed Web of Science ®Google Scholar
• Vehreschild JJ, Birtel A, Vehreschild MJ, et al. Mucormycosis treated with posaconazole: review of 96 case reports. Crit Rev Microbiol. 2013;39:310–324. doi:10.3109/1040841X.2012.711741
   PubMed Web of Science ®Google Scholar
• van Burik JA, Hare RS, Solomon HF, et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis. 2006;42:e61–5. doi:10.1086/500212
   PubMed Web of Science ®Google Scholar
• Ananda-Rajah MR, Kontoyiannis D. Isavuconazole: a new extended spectrum triazole for invasive mold diseases. Future Microbiol. 2015;10:693–708. doi: 10.2217/fmb.15.34
   PubMed Web of Science ®Google Scholar
• Bagshaw E, Enoch DA, Blackney M, et al. Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK. Future Microbiol. 2018;13:1283–1293. doi:10.2217/fmb-2018-0119
   PubMed Web of Science ®Google Scholar
• Perfect JR, Cornely OA, Heep M, et al. Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: challenges and lessons of the VITAL trial. Mycoses. 2018;61(7):420–429. doi:10.1111/myc.12769
   PubMed Web of Science ®Google Scholar
• Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16:828–837.
   PubMed Web of Science ®Google Scholar
• Falci DR, Pasqualotto AC. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infect Drug Resist. 2013;6:163–174. doi: 10.2147/IDR.S51340
   PubMedGoogle Scholar
• Natesan SK, Chandrasekar PH. Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations. Infect Drug Resist. 2016;9:291–300. doi: 10.2147/IDR.S102207
   PubMed Web of Science ®Google Scholar
• Guinea J, Pelaez T, Recio S, et al. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother. 2008;52:1396–1400. doi:10.1128/AAC.01512-07
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Chakrabarti A, Chowdhary A, et al. Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales. Antimicrob Agents Chemother. 2015;59(3):1745–1750. doi:10.1128/AAC.04435-14
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Jensen RH, Meletiadis J. In vitro activity of isavuconazole and comparators against clinical Isolates of the Mucorales order. Antimicrob Agents Chemother. 2015;59(12):7735–7742. doi:10.1128/AAC.01919-15.
   PubMed Web of Science ®Google Scholar
• Groll AH, Desai A, Han D, et al. Pharmacokinetic assessment of drug-drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults. Clin Pharmacol Drug Dev. 2017;6(1):76–85. doi:10.1002/cpdd.284
   PubMed Web of Science ®Google Scholar
• Sansone-Parsons A, Krishna G, Martinho M, et al. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacother. 2007;27(6):825–834. doi:10.1592/phco.27.6.825
   PubMed Web of Science ®Google Scholar
• Collins J, Shea K, Parsad S, et al. The impact of initiating posaconazole on tacrolimus pharmacokinetics in allogeneic stem cell transplantation. J Oncol Pharm Pract. 2020;26(1):5–12. doi:10.1177/1078155219833440
   PubMed Web of Science ®Google Scholar
• Moton A, Ma L, Krishna G, et al. Effects of oral posaconazole on the pharmacokinetics of sirolimus. Curr Med Res Opin. 2009;25(3):701–707. DOI:10.1185/03007990802644209
   PubMed Web of Science ®Google Scholar
• Manesh A, John AO, Mathew B, et al. Posaconazole: an emerging therapeutic option for invasive rhino-orbito-cerebral mucormycosis. Mycoses. 2016;59(12):765–772. DOI:10.1111/myc.12529
   PubMed Web of Science ®Google Scholar
• Epstein JB, Kupferman SB, Zabner R, et al. Early diagnosis and successful management of oral mucormycosis in a hematopoietic stem cell transplant recipient: case report and literature review. Support Care Cancer. 2016;24(8):3343–3346. DOI:10.1007/s00520-016-3170-x
   PubMed Web of Science ®Google Scholar
• Abboud CS, Bergamasco MD, Baia CE, et al. Case report of hepatic mucormycosis after liver transplantation: successful treatment with liposomal amphotericin B followed by posaconazole sequential therapy. Transplant Proc. 2012;44(8):2501–2502. DOI:10.1016/j.transproceed.2012.07.042
   PubMed Web of Science ®Google Scholar
• Ashkenazi-Hoffnung L, Bilavsky E, Avitzur Y, et al. Successful treatment of cutaneous zygomycosis with intravenous amphotericin B followed by oral posaconazole in a multivisceral transplant recipient. Transplantation. 2010;90(10):1133–1135. DOI:10.1097/TP.0b013e3181f86916
   PubMed Web of Science ®Google Scholar
• Tobon AM, Arango M, Fernandez D, et al. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin Infect Dis. 2003;36(11):1488–1491. DOI:10.1086/375075
   PubMed Web of Science ®Google Scholar
• Tverdek FP, Heo ST, Aitken SL, et al. Real-life assessment of the safety and effectiveness of the new tablet and intravenous formulations of posaconazole in the prophylaxis of invasive fungal infections via analysis of 343 courses. Antimicrob Agents Chemother. 2017;61(8):61. DOI:10.1128/AAC.00188-17
   Web of Science ®Google Scholar
• Auberger J, Lass-Florl C, Aigner M, et al. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study. J Antimicrob Chemother. 2012;67(9):2268–2273. DOI:10.1093/jac/dks189
   PubMed Web of Science ®Google Scholar
• Shirley M, Scott LJ. Isavuconazole: a Review in invasive aspergillosis and mucormycosis. Drugs. 2016;76:1647–1657. doi: 10.1007/s40265-016-0652-6
   PubMed Web of Science ®Google Scholar
• Peixoto D, Gagne LS, Hammond SP, et al. Isavuconazole treatment of a patient with disseminated mucormycosis. J Clin Microbiol. 2014;52(3):1016–1019. DOI:10.1128/JCM.03176-13
   PubMed Web of Science ®Google Scholar
• Miceli MH, Kauffman CA. Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect Dis. 2015;61:1558–1565. doi: 10.1093/cid/civ571
   PubMed Web of Science ®Google Scholar
• Graves B, Morrissey CO, Wei A, et al. Isavuconazole as salvage therapy for mucormycosis. Med Mycol Case Rep. 2016;11:36–39. doi:10.1016/j.mmcr.2016.03.002
   PubMed Web of Science ®Google Scholar
• Ervens J, Ghannoum M, Graf B, et al. Successful isavuconazole salvage therapy in a patient with invasive mucormycosis. Infection. 2014;42(2):429–432. doi:10.1007/s15010-013-0552-6.
   PubMed Web of Science ®Google Scholar
• Rausch CR, DiPippo AJ, Bose P, et al. Breakthrough fungal infections in patients with leukemia receiving isavuconazole. Clin Infect Dis. 2018;67:1610–1613. doi:10.1093/cid/ciy406
   PubMed Web of Science ®Google Scholar
• Dagher H, Hachem R, Chaftari AM, et al. Real-world use of isavuconazole as primary therapy for invasive fungal infections in high-risk patients with hematologic malignancy or stem cell transplant. J Fungi (Basel). 2022;8(1):8.74–8. DOI:10.3390/jof8010074
   Google Scholar
• Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387:760–769. doi:10.1016/S0140-6736(15)01159-9
   PubMed Web of Science ®Google Scholar
• Monforte A, Los-Arcos I, Martin-Gomez MT, et al. Safety and effectiveness of isavuconazole treatment for fungal infections in solid organ transplant recipients (ISASOT Study). Microbiol Spectr. 2022;10(1):e0178421. DOI:10.1128/spectrum.01784-21
   PubMed Web of Science ®Google Scholar
• Kronig I, Masouridi-Levrat S, Chalandon Y, et al. Clinical considerations of isavuconazole administration in high-risk hematological patients: a single-center 5-year experience. Mycopathologia. 2021;186(6):775–788. doi:10.1007/s11046-021-00583-9
   PubMed Web of Science ®Google Scholar
• Patterson TF, Thompson GR 3rd, Denning DW, et al. Executive summary: practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):433–442. doi:10.1093/cid/ciw444
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Desai A, Kowalski D, et al. Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH. Int J Clin Pharmacol Ther. 2016;54(8):572–580. doi:10.5414/CP202434
   PubMed Web of Science ®Google Scholar
• Furfaro E, Signori A, Di Grazia C, et al. Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy. J Antimicrob Chemother. 2019;74(8):2341–2346. doi:10.1093/jac/dkz188
   PubMed Web of Science ®Google Scholar
• Desai AV, Kovanda LL, Hope WW, et al. Exposure-response relationships for isavuconazole in patients with invasive Aspergillosis and other filamentous fungi. Antimicrob Agents Chemother. 2017;61(12):61.34–9. doi:10.1128/AAC.01034-17
   Web of Science ®Google Scholar
• Tacke D, Koehler P, Markiefka B, et al. Our 2014 approach to mucormycosis. Mycoses. 2014;57(9):519–524. doi:10.1111/myc.12203.
   PubMed Web of Science ®Google Scholar
• Candoni A, Aversa F, Busca A, et al. Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data. J Chemother. 2015;27(1):1–12. doi:10.1179/1973947814Y.0000000224
   PubMed Web of Science ®Google Scholar
• Pagano L, Cornely OA, Busca A, et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica. 2013;98(10):e127–30. doi:10.3324/haematol.2012.083063
   PubMed Web of Science ®Google Scholar
• Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47(3):364–371. doi:10.1086/589857
   PubMed Web of Science ®Google Scholar
• Spellberg B, Fu Y, Edwards JE Jr., et al. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother. 2005;49(2):830–832. doi:10.1128/AAC.49.2.830-832.2005
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Gebremariam T, Fu Y, et al. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother. 2008;52(4):1556–1558. DOI:10.1128/AAC.01458-07
   PubMed Web of Science ®Google Scholar
• Gebremariam T, Gu Y, Singh S, et al. Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis. J Antimicrob Chemother. 2021;76(10):2636–2639. doi:10.1093/jac/dkab233
   PubMed Web of Science ®Google Scholar
• Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox-AmBisome therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother. 2012;67:715–722. doi:10.1093/jac/dkr375
   PubMed Web of Science ®Google Scholar
• Hoenigl M, Sprute R, Egger M, et al. The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs. 2021;81(15):1703–1729. doi:10.1007/s40265-021-01611-0
   PubMed Web of Science ®Google Scholar
• Gebremariam T, Gu Y, Alkhazraji S, et al. The combination treatment of fosmanogepix and liposomal Amphotericin B is superior to monotherapy in treating experimental invasive mold infections. Antimicrob Agents Chemother. 2022;66(7):e0038022. doi:10.1128/aac.00380-22
   PubMed Web of Science ®Google Scholar
• Limper AH, Knox KS, Sarosi GA, et al. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011;183(1):96–128. doi:10.1164/rccm.2008-740ST
   PubMed Web of Science ®Google Scholar
• Muthu V, Agarwal R, Patel A, et al. Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India. Lancet Infect Dis. 2022;22(9):22;e240–e253. doi:10.1016/S1473-3099(22)00124-4
   PubMed Web of Science ®Google Scholar